HEMODYNAMIC EFFECTS AND PHARMACOKINETICS OF A NEW SELECTIVE BETA-1-ADRENOCEPTOR AGONIST, PRENALTEROL, AND ITS INTERACTION WITH METOPROLOL IN MAN

被引:87
作者
RONN, O
GRAFFNER, C
JOHNSSON, G
JORDO, L
LUNDBORG, P
WIKSTRAND, J
机构
[1] AB HASSLE,RES LABS,S-43120 MOLNDAL 1,SWEDEN
[2] SAHLGRENS HOSP,DEPT MED 2,S-41345 GOTHENBURG,SWEDEN
[3] SAHLGRENS HOSP,DEPT CLIN PHYSIOL,S-41345 GOTHENBURG,SWEDEN
关键词
haemodynamics; metoprolol; pharmacokinetics; prenalterol;
D O I
10.1007/BF00563552
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The haemodynamic effects of the selective β1-adrenoceptor agonist prenalterol were studied in healthy subjects before and after therapeutic doses of the selective β1-adrenoceptor blocker metoprolol. Plasma levels of the drugs were also determined in order to calculate certain pharmacokinetic variables. Intravenous infusion of prenalterol 0.13, 0.25 and 0.50 mg induced a dose-dependent decrease in total electromechanical systole (QA2) and pre-ejection period (PEP). The effect on left ventricular ejection time (LVET) was not significant. Increases in systolic blood pressure and heart rate were dose-dependent. Diastolic blood pressure did not change significantly. When metoprolol had been administered in a cumulative dose of 150 mg (mean maximal plasma level, 284 nmol/1) prenalterol had to be administered in doses that were twelve times higher than before the β-blocker in order to induce the same haemodynamic effects. Prenalterol was rapidly distributed with an average half life of 8 min. This indicates that distribution equilibrium will be achieved within 30 min after intravenous administration. The overall elimination rate in the post-distributive phase corresponded to an average half life of 2.0 h. © 1979 Springer-Verlag.
引用
收藏
页码:9 / 13
页数:5
相关论文
共 10 条
[1]  
ABLAD B, 1975, ACTA PHARMACOL TO S5, V36
[2]   DIFFERENTIATION OF CARDIAC CHRONOTROPIC AND INOTROPIC EFFECTS OF BETA-ADRENOCEPTOR AGONISTS [J].
CARLSSON, E ;
DAHLOF, CG ;
HEDBERG, A ;
PERSSON, H ;
TANGSTRAND, B .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1977, 300 (02) :101-105
[3]  
ERVIK M, 1975, ACTA PHARMACOL TOX, V36, P136
[4]  
JOHNSSON G, 1975, ACTA PHARMACOL TOX, V36, P31
[5]   HEMODYNAMIC AND TOLERANCE STUDIES IN MAN OF A NEW, ORALLY ACTIVE, SELECTIVE BETA-1-ADRENOCEPTOR AGONIST H 80-62 [J].
JOHNSSON, G ;
JORDO, L ;
LUNDBORG, P ;
RONN, O ;
WELINFOGELBERG, I ;
WIKSTRAND, J .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1978, 13 (03) :163-170
[6]   HUMAN PHARMACOLOGY STUDIES WITH A NEW, ORALLY ACTIVE STIMULANT OF CARDIAC ADRENERGIC BETA-RECEPTORS [J].
KNAUS, M ;
PFISTER, B ;
DUBACH, UC ;
IMHOF, PR .
AMERICAN HEART JOURNAL, 1978, 95 (05) :602-610
[7]   CSTRIP, A FORTRAN-4 COMPUTER-PROGRAM FOR OBTAINING INITIAL POLYEXPONENTIAL PARAMETER ESTIMATES [J].
SEDMAN, AJ ;
WAGNER, JG .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1976, 65 (07) :1006-1010
[8]   DOBUTAMINE - DEVELOPMENT OF A NEW CATECHOLAMINE TO SELECTIVELY INCREASE CARDIAC CONTRACTILITY [J].
TUTTLE, RR ;
MILLS, J .
CIRCULATION RESEARCH, 1975, 36 (01) :185-196
[9]   BEDSIDE TECHNICS FOR EVALUATION OF VENTRICULAR FUNCTION IN MAN [J].
WEISSLER, AM ;
HARRIS, WS ;
SCHOENFELD, CD .
AMERICAN JOURNAL OF CARDIOLOGY, 1969, 23 (04) :577-+
[10]  
WIKSTRAND J, 1978, BRIT HEART J, V40, P256